RPL17 and non-small cell lung carcinoma: Conversely, we found positive and significant enrichment of gene sets associated with most macrophage subtypes in NSCLC and liver cancer patients who experienced complete response (CR) or partial response (PR) while receiving anti-PD-1 (Figs 8, 9 and S16).